Rosetta Genomics Ltd.
ROSG
ROSG was delisted on the 21st of May, 2018.
10 hedge funds and large institutions have $280K invested in Rosetta Genomics Ltd. in 2017 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
11% more funds holding
Funds holding: 9 → 10 (+1)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
40% less capital invested
Capital invested by funds: $467K → $280K (-$187K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$141K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$28.4K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$709 |
| 4 |
Credit Agricole
Montrouge Cedex,
France
|
+$3 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$149K |
| 2 |
HCM
Highlander Capital Management
Short Hills,
New Jersey
|
-$9.52K |
| 3 |
VF
Virtu Financial
New York
|
-$3.56K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Morgan Stanley
New York
| $209K | +$141K | +179,907 | +92% |
|
|
VF
2
Virtu Financial
New York
| $43K | -$3.56K | -4,533 | -6% |
|
|
3
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $20K | +$28.4K | +36,171 | New |
|
|
HCM
4
Highlander Capital Management
Short Hills,
New Jersey
| $5K | -$9.52K | -12,136 | -58% |
|
|
5
UBS Group
Zurich,
Switzerland
| $3K | +$709 | +904 | +20% |
|
|
SM
6
Sabby Management
Miami Beach,
Florida
| – | -$149K | -141,741 | Closed |
|
|
7
Credit Agricole
Montrouge Cedex,
France
| – | +$3 | +4 | New |
|
ROSG Hedge Fund Activity: Q4 2017 in Review
10 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Rosetta Genomics Ltd. (ROSG) for Q4 2017, worth a combined $280K — down 40% from $467K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new ROSG positions and 1 closed out — a net gain of 1 holder — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $141K. The largest seller was Sabby Management, exiting entirely with an estimated $149K sold.
- 10 institutional investors held Rosetta Genomics Ltd. (ROSG) as of Q4 2017, up from 9 in Q3 2017.
- Funds reported $280K of Rosetta Genomics Ltd. stock for Q4 2017, down 40% quarter-over-quarter.
- 2 funds opened new Rosetta Genomics Ltd. positions in Q4 2017 and 1 closed out, a net change of +1 holder.
- The largest Rosetta Genomics Ltd. buyer in Q4 2017 was Morgan Stanley, an estimated $141K added.
- The largest Rosetta Genomics Ltd. seller in Q4 2017 was Sabby Management, an estimated $149K sold.
Based on aggregated 13F filings for Q4 2017.